Ildong Holdings Co Ltd - Asset Resilience Ratio
Ildong Holdings Co Ltd (000230) has an Asset Resilience Ratio of 0.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ildong Holdings Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Ildong Holdings Co Ltd's Asset Resilience Ratio has changed over time. See Ildong Holdings Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ildong Holdings Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Ildong Holdings Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.20 Billion | 0.15% |
| Total Liquid Assets | ₩1.20 Billion | 0.15% |
Asset Resilience Insights
- Limited Liquidity: Ildong Holdings Co Ltd maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ildong Holdings Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ildong Holdings Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Ildong Holdings Co Ltd (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Ildong Holdings Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.15% | ₩1.20 Billion ≈ $814.19K |
₩802.86 Billion ≈ $544.09 Million |
-1.64pp |
| 2024-12-31 | 1.79% | ₩15.28 Billion ≈ $10.35 Million |
₩854.70 Billion ≈ $579.22 Million |
-1.78pp |
| 2023-12-31 | 3.57% | ₩31.29 Billion ≈ $21.21 Million |
₩877.00 Billion ≈ $594.33 Million |
-0.77pp |
| 2022-12-31 | 4.34% | ₩37.42 Billion ≈ $25.36 Million |
₩862.55 Billion ≈ $584.54 Million |
+1.49pp |
| 2021-12-31 | 2.84% | ₩26.19 Billion ≈ $17.75 Million |
₩920.76 Billion ≈ $623.99 Million |
+2.21pp |
| 2020-12-31 | 0.64% | ₩5.09 Billion ≈ $3.45 Million |
₩799.40 Billion ≈ $541.74 Million |
+0.23pp |
| 2019-12-31 | 0.41% | ₩3.30 Billion ≈ $2.23 Million |
₩805.63 Billion ≈ $545.96 Million |
-1.28pp |
| 2018-12-31 | 1.69% | ₩4.49 Billion ≈ $3.04 Million |
₩265.47 Billion ≈ $179.90 Million |
+0.75pp |
| 2017-12-31 | 0.94% | ₩2.59 Billion ≈ $1.76 Million |
₩274.84 Billion ≈ $186.25 Million |
-1.55pp |
| 2016-12-31 | 2.49% | ₩5.09 Billion ≈ $3.45 Million |
₩204.09 Billion ≈ $138.31 Million |
+1.93pp |
| 2015-12-31 | 0.56% | ₩3.98 Billion ≈ $2.69 Million |
₩705.64 Billion ≈ $478.20 Million |
+0.16pp |
| 2014-12-31 | 0.40% | ₩2.48 Billion ≈ $1.68 Million |
₩620.35 Billion ≈ $420.40 Million |
-0.03pp |
| 2013-12-31 | 0.43% | ₩2.68 Billion ≈ $1.82 Million |
₩628.21 Billion ≈ $425.73 Million |
-0.19pp |
| 2012-12-31 | 0.62% | ₩3.35 Billion ≈ $2.27 Million |
₩541.71 Billion ≈ $367.11 Million |
-0.43pp |
| 2011-12-31 | 1.05% | ₩5.35 Billion ≈ $3.63 Million |
₩511.65 Billion ≈ $346.74 Million |
-2.64pp |
| 2010-12-31 | 3.68% | ₩19.57 Billion ≈ $13.27 Million |
₩531.23 Billion ≈ $360.01 Million |
+2.68pp |
| 2009-12-31 | 1.00% | ₩4.96 Billion ≈ $3.36 Million |
₩495.53 Billion ≈ $335.82 Million |
-0.34pp |
| 2008-12-31 | 1.34% | ₩5.43 Billion ≈ $3.68 Million |
₩404.79 Billion ≈ $274.32 Million |
+0.48pp |
| 2007-12-31 | 0.86% | ₩2.90 Billion ≈ $1.96 Million |
₩336.03 Billion ≈ $227.73 Million |
-0.07pp |
| 2006-12-31 | 0.93% | ₩2.64 Billion ≈ $1.79 Million |
₩283.77 Billion ≈ $192.31 Million |
+0.57pp |
| 2005-12-31 | 0.36% | ₩941.26 Million ≈ $637.88K |
₩258.07 Billion ≈ $174.89 Million |
-0.09pp |
| 2004-12-31 | 0.45% | ₩1.05 Billion ≈ $709.94K |
₩232.19 Billion ≈ $157.35 Million |
-0.30pp |
| 2003-12-31 | 0.75% | ₩1.65 Billion ≈ $1.12 Million |
₩218.82 Billion ≈ $148.29 Million |
+0.20pp |
| 2002-12-31 | 0.56% | ₩1.09 Billion ≈ $741.62K |
₩195.90 Billion ≈ $132.76 Million |
-0.14pp |
| 2001-12-31 | 0.70% | ₩1.27 Billion ≈ $863.51K |
₩183.11 Billion ≈ $124.09 Million |
-0.21pp |
| 2000-12-31 | 0.91% | ₩1.70 Billion ≈ $1.15 Million |
₩187.75 Billion ≈ $127.23 Million |
+0.78pp |
| 1999-12-31 | 0.12% | ₩234.02 Million ≈ $158.59K |
₩188.81 Billion ≈ $127.96 Million |
-- |
About Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the… Read more